07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

AMR-102: Phase I data

A Phase I trial in 48 healthy volunteers showed that AMR-102 was well tolerated with no serious adverse events reported. Amarin said AMR-102 did not inhibit the bioavailability of either active component of the product...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

AMR102: Clinical trial ongoing

Amarin completed dosing in an open-label, U.S. clinical trial evaluating multiple doses of AMR102 in 48 healthy volunteers. Amarin's Vascepa is approved in the U.S. as an adjunct to diet to reduce triglyceride levels in...